The tumor growth rate in the patients with metastatic colorectal cancer was faster after bevacizumab (anti-VEGF) treatment and also possibly accelerated by surgery due to increased angiogenic cytokines such as plasmatic VEGF (Cacheux et al., 2008). This evidence concerns the gene VEGFA and neoplasm.